Hepatocellular carcinoma: The place of new medical therapies

Therapeutic Advances in Gastroenterology

Volumn 3, Issue 4, 2010, Pages 259-267

  Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Barcelona Clinic liver cancer staging system; Hepatocellular carcinoma; Liver cancer; Sorafenib; Transarterial chemoembolization; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; BRIVANIB; CETUXIMAB; CISPLATIN; DOXORUBICIN; ERLOTINIB; GEMCITABINE; IODINATED POPPYSEED OIL; OXALIPLATIN; PLACEBO; SORAFENIB; SUNITINIB; THALIDOMIDE;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEPATOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; METASTASIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TUMOR BIOPSY;

EID: 77954198843     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X10362278     Document Type: Review

References (47)

1. Abou-Alfa, G., Johnson, P., Knox, J., Davidenko, I., Lacava, J., Leung, T. et al. (2007) Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Eur J Cancer 5(Suppl.): 259.
2. Abou-Alfa, G.K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A. et al. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300.
3. Asnacios, A., Fartoux, L., Romano, O., Tesmoingt, C., Louafi, S.S., Mansoubakht, T. et al. (2008) Gemcitabine plus oxaliplatin (Gemox) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 112: 2733-2739.
4. Bolondi, L., Caspary, W., Bennouna, J., Thomson, B., van Steenbergen, W., Degos, F. et al. (2008) Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the sharp trial. J Clin Oncol 26(Suppl.): A129.
5. Bruix, J. and Llovet, J.M. (2009) Major achievements in hepatocellular carcinoma. Lancet 373: 614-616.
6. Bruix, J., Sala, M. and Llovet, J.M. ( 2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127: S179-S188.
7. Bruix, J. and Sherman, M. ( 2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236.
8. Cheng, A., Kang, Y., Chen, Z., Tsao, C., Qin, S., Kim, J. et al. (2008) Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 26(Suppl.): A4509.
9. Duran, I., Hotte, S.J., Hirte, H., Chen, E.X., Maclean, M., Turner, S. et al. (2007) Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 13: 4849-4857.
10. Faivre, S., Raymond, E., Boucher, E., Douillard, J., Lim, H.Y., Kim, J.S. et al. (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10: 794-800.
11. Garcia, M., Jemal, A., Ward, E.M., Center, M.M., Hao, Y., Siegel, R.L. et al. (2007) Global Cancer Facts and Figures 2007. www.cancer.org
12. Hilberg, F., Roth, G.J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U. et al. (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68: 4774-4782.
13. Himmelsbach, K., Sauter, D., Baumert, T., Ludwig, L., Blum, H. and Hildt, E. (2009) New aspects of an anti-tumor drug: sorafenib efficiently inhibits HCV replication. Gut 58: 1644-1653.
14. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
15. Huynh, H., Ngo, V.C., Fargnoli, J., Ayers, M., Soo, K.C., Koong, H.N. et al. (2008) Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14: 6146-6153.
16. Li, Z., Hu, D.Y., Chu, Q., Wu, J.H., Gao, C., Zhang, Y.Q. et al. (2004) Cell apoptosis and regeneration of hepatocellular carcinoma after transarterial chemoembolization. World J Gastroenterol 10: 1876-1880.
17. Lin, A.Y., Fisher, G.A., So, S., Tang, C. and Levitt, L. ( 2008) Phase II study of imatinib in unresectable hepatocellular carcinoma. Am J Clin Oncol 31: 84-88.
18. Liu, W., Makrauer, F.L., Qamar, A.A., Janne, P.A. and Odze, R.D. ( 2007) Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 5: 917-920.
19. Livraghi, T., Meloni, F., Di Stasi, M., Rolle, E., Solbiati, L., Tinelli, C. et al. (2008) Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47: 82-89.
20. Llovet, J.M., Bru, C. and Bruix, J. ( 1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338.
21. Llovet, J.M. and Bruix, J. ( 2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37: 429-442.
22. Llovet, J.M. and Bruix, J. ( 2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1): S20-S37.
23. Llovet, J.M., Di Bisceglie, A.M., Bruix, J., Kramer, B.S., Lencioni, R., Zhu, A.X. et al. (2008 a) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711.
24. Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F. et al. (2008 b) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
25. Llovet, J.M., Schwartz, M. and Mazzaferro, V. ( 2005) Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25: 181-200.
26. Marelli, L., Stigliano, R., Triantos, C., Senzolo, M., Cholongitas, E., Davies, N. et al. (2007) Transarterial Therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30: 6-25.
27. Mathurin, P., Rixe, O., Carbonell, N., Bernard, B., Cluzel, P., Bellin, M.F. et al. (1998) Review article: overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis? Aliment Pharmacol Ther 12: 111-126.
28. Paez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vinals, F. et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
29. Peck-Radosavljevic, M., Greten, T.F., Lammer, J., Rosmorduc, O., Sangro, B., Santoro, A. et al. (2010) Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol (in press).
30. Perilongo, G., Maibach, R., Shafford, E., Brugieres, L., Brock, P., Morland, B. et al. (2009) Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361: 1662-1670.
31. Philip, P.A., Mahoney, M.R., Allmer, C., Thomas, J., Pitot, H.C., Kim, G. et al. (2005) Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23: 6657-6663.
32. Pinter, M., Sieghart, W., Graziadei, I., Vogel, W., Maieron, A., Konigsberg, R. et al. (2009) Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 14: 70-76.
33. Raoul, J.-L., Finn, R.S., Kang, Y.-K., Park, J.-W., Harris, R., Coric, V. et al. (2009) An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol 27(Suppl 1): A4577.
34. Sangiovanni, A., Del Ninno, E., Fasani, P., de Fazio, C., Ronchi, G., Romeo, R. et al. (2004) Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126: 1005-1014.
35. Sergio, A., Cristofori, C., Cardin, R., Pivetta, G., Ragazzi, R., Baldan, A. et al. (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103: 914-921.
36. Siegel, A.B., Cohen, E.I., Ocean, A., Lehrer, D., Goldenberg, A., Knox, J.J. et al. (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26: 2992-2998.
37. Thomas, M.B., Chadha, R., Glover, K., Wang, X., Morris, J., Brown, T. et al. (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110: 1059-1067.
38. Thomas, M.B., Morris, J.S., Chadha, R., Iwasaki, M., Kaur, H., Lin, E. et al. (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27: 843-850.
39. Thomas, M.B., O'Beirne, J.P., Furuse, J., Chan, A.T., Abou-Alfa, G. and Johnson, P. ( 2008) Systemic therapy for hepatocellular carcinoma: cytotoxic
40. chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 15: 1008-1014.
41. Toh, H.-C., Chen, P.-J., Carr, B.I., Knox, J.J., Gill, S., Steinberg, J. et al. (2009) A Phase II study of Abt-869 in hepatocellular carcinoma (HCC). J Clin Oncol 27(Suppl.): A4581.
42. Wilhelm, S.M., Carter, C., Tang, L., Wilkie, D., Mcnabola, A., Rong, H. et al. (2004) Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/Mek/Erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.
43. Yang, Z.F., Poon, R.T., To, J., Ho, D.W. and Fan, S.T. ( 2004) The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma. Cancer Res 64: 5496-5503.
44. Zhang, B.H., Yang, B.H. and Tang, Z.Y. ( 2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 417-422.
45. Zhu, A.X., Blaszkowsky, L.S., Ryan, D.P., Clark, J.W., Muzikansky, A., Horgan, K. et al. (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 1898-1903.
46. Zhu, A.X., Sahani, D.V., Duda, D.G., Di Tomaso, E., Ancukiewicz, M., Catalano, O.A. et al. (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27: 3027-3035.
47. Zhu, A.X., Stuart, K., Blaszkowsky, L.S., Muzikansky, A., Reitberg, D.P., Clark, J.W. et al. (2007) Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110: 581-589.